AM1476 Receives Orphan Drug Designation for Treating Systemic Sclerosis

AM1476, a first-in-class peripheral acting serotonin receptor antagonist, has been granted US and EU orphan drug designation as an anti-fibrotic treatment for systemic sclerosis. The drug, which is a selective peripheral acting 5-HT2B receptor small molecule antagonist, has shown efficacy in treating both skin and lung manifestations of systemic sclerosis. Systemic sclerosis is a chronic autoimmune disease characterized by inflammation and fibrosis, and there are currently no treatments that effectively stop or reverse scarring in both skin and lung tissue.